05:12 PM EST, 11/19/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said late Wednesday the US Food and Drug Administration has approved Eylea HD for the treatment of patients with macular edema.

The Eylea HD Injection 8 mg is indicated for the treatment following retinal vein occlusion with up to every 8-week dosing after an initial monthly dosing period, the company said.

The FDA also approved an every 4-week dosing option for some patients who may benefit from resuming this dosing schedule across approved indications, including wet age-related macular degeneration and diabetic macular edema, it added.